Raymond James & Associates Has Boosted Its Royal Gold (RGLD) Stake; 8 Analysts Covering CymaBay Therapeutics, Inc. (CBAY)

April 17, 2018 - By Ellis Scott

Royal Gold, Inc. (NASDAQ:RGLD) Logo

Among 8 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 30 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald initiated it with “Buy” rating and $16.0 target in Tuesday, September 19 report. Oppenheimer maintained the stock with “Buy” rating in Wednesday, March 21 report. The firm has “Buy” rating by Piper Jaffray given on Tuesday, July 25. The firm earned “Buy” rating on Thursday, March 15 by Piper Jaffray. The firm has “Buy” rating given on Monday, July 17 by H.C. Wainwright. The firm earned “Buy” rating on Wednesday, January 24 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, March 28 by H.C. Wainwright. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by H.C. Wainwright on Tuesday, September 8. H.C. Wainwright maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) rating on Wednesday, January 4. H.C. Wainwright has “Neutral” rating and $2.50 target. The company was maintained on Monday, September 11 by Piper Jaffray. See CymaBay Therapeutics, Inc. (NASDAQ:CBAY) latest ratings:

16/04/2018 Broker: Roth Capital Rating: Buy New Target: $27.0000 Maintain
11/04/2018 Broker: Leerink Swann Rating: Buy New Target: $20.0000 Maintain
11/04/2018 Broker: Evercore Rating: Buy
28/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Initiate
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $16.0000 Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: SunTrust Rating: Buy New Target: $19.0 Maintain
16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $16.0 Maintain
13/02/2018 Broker: Evercore Rating: Outperform Initiates Coverage On

Raymond James & Associates increased Royal Gold Inc (RGLD) stake by 88.61% reported in 2017Q4 SEC filing. Raymond James & Associates acquired 32,054 shares as Royal Gold Inc (RGLD)’s stock declined 2.56%. The Raymond James & Associates holds 68,228 shares with $5.60M value, up from 36,174 last quarter. Royal Gold Inc now has $5.87B valuation. The stock increased 0.17% or $0.15 during the last trading session, reaching $89.61. About 486,512 shares traded. Royal Gold, Inc. (NASDAQ:RGLD) has risen 22.48% since April 17, 2017 and is uptrending. It has outperformed by 10.93% the S&P500.

Investors sentiment decreased to 1.17 in 2017 Q4. Its down 0.24, from 1.41 in 2017Q3. It fall, as 27 investors sold RGLD shares while 79 reduced holdings. 47 funds opened positions while 77 raised stakes. 47.73 million shares or 2.38% more from 46.63 million shares in 2017Q3 were reported. Zacks Inv Management accumulated 10,635 shares. Jpmorgan Chase And invested in 144,845 shares. Benchmark Capital Advsrs holds 0.4% of its portfolio in Royal Gold, Inc. (NASDAQ:RGLD) for 6,200 shares. Ahl Prns Limited Liability Partnership accumulated 92,240 shares or 0.12% of the stock. Toronto Dominion State Bank holds 0% or 2,214 shares in its portfolio. Citadel Advsr Lc stated it has 60,444 shares. Indexiq Advsrs Ltd Liability holds 0.07% or 24,051 shares in its portfolio. Tocqueville Asset LP has invested 0.74% of its portfolio in Royal Gold, Inc. (NASDAQ:RGLD). Stone Ridge Asset Mgmt Limited Liability Company holds 0.01% or 2,667 shares in its portfolio. Pring Turner Cap Group has invested 3.55% in Royal Gold, Inc. (NASDAQ:RGLD). Legal General Group Inc Public Limited invested in 98,491 shares. Old Mutual Glob (Uk) Limited accumulated 1,177 shares. 3,200 are owned by Oz Limited Partnership. Oxbow Advsr Lc, a Texas-based fund reported 10,540 shares. Telemus Capital Limited Liability owns 100 shares for 0% of their portfolio.

Among 12 analysts covering Royal Gold Inc. (NASDAQ:RGLD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Royal Gold Inc. had 53 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, March 6 by Scotia Capital. The firm has “Buy” rating given on Tuesday, September 19 by RBC Capital Markets. BMO Capital Markets downgraded the stock to “Market Perform” rating in Thursday, January 14 report. The rating was maintained by RBC Capital Markets with “Buy” on Monday, July 10. The stock has “Buy” rating by Canaccord Genuity on Monday, April 9. The firm earned “Market Perform” rating on Thursday, June 15 by Raymond James. The firm has “Mkt Perform” rating by FBR Capital given on Wednesday, July 6. The company was downgraded on Monday, March 14 by Raymond James. The rating was maintained by RBC Capital Markets with “Buy” on Tuesday, April 3. As per Monday, October 23, the company rating was maintained by RBC Capital Markets.

Raymond James & Associates decreased Activision Blizzard Inc (NASDAQ:ATVI) stake by 52,741 shares to 429,952 valued at $27.23 million in 2017Q4. It also reduced C H Robinson Worldwide Inc (NASDAQ:CHRW) stake by 9,113 shares and now owns 215,520 shares. Ctrip Com Intl Ltd (NASDAQ:CTRP) was reduced too.

Since December 13, 2017, it had 0 buys, and 5 selling transactions for $644,160 activity. The insider WENGER STEFAN sold 1,500 shares worth $127,500.

The stock decreased 3.47% or $0.45 during the last trading session, reaching $12.66. About 637,343 shares traded. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 197.77% since April 17, 2017 and is uptrending. It has outperformed by 186.22% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $740.93 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Royal Gold, Inc. (NASDAQ:RGLD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>